康莱特联合GP方案治疗晚期非小细胞肺癌临床疗效观察

摘要

目的:观察康莱特联合GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌患者的有效性.方法:将72例晚期非小细胞肺癌患者随机分为试验组和对照组,对照组予GP方案化疗,试验组予GP化疗方案+康莱特联合治疗,比较两组治疗有效率、对生活质量影响及肿瘤标志物水平.结果:两组间治疗有效率相当,差异无统计学意义(P>0.05);试验组KPS评分改善优于对照组,差异有统计学意义(P<0.05);试验组肿瘤标志物水平低于对照组.结论:康莱特联合GP方案化疗不影响晚期非小细胞肺癌患者治疗有效率,但可降低患者血清糖链抗原CA-125、神经烯醇化酯酶(NSE)水平,明显改善患者生活质量.%Objective:To analysis Kanglaite combined with GP regimen (Gemcitabine + Cisplatin)and GP regi-men only in the treatment of advanced non small cell lung cancer(NSCLC),aims to estimate the validity of Kanglaite in treating NSCLC.Methods:The data of 72 cases of advanced NSCLC patients were randomly divided into experi-mental group and control group,control group received GP chemotherapy,the test group received GP chemotherapy +Kanglaite combined treatment,efficiency and effect on quality of life of two groups were compared.Results:Effective rate of Kanglaite + GP was equal to GP in treating NSCLC(P > 0.05).Life quality improved significantly in Kanglaite+ GP group(P< 0.05).Conclusion:Kanglaite significantly improved life quality of NSCLC patients.It's worthy of clinical promotion.